R

Roche

Global pharmaceuticals and diagnostics company

Associate Finance Manager

Full-Time
$140.2k - $150.8k/yr+ Annual bonus
Mid
Master's
Indianapolis, IN, USA
HybridUp to 2 days of telecommuting per week.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A Master's degree or foreign equivalent in Finance, Business, or a related field.
  • At least 4 years of experience in the job offered or a related Financial Planning and Analysis position.
  • At least 3 years of experience with accounting knowledge and financial statement analysis, including supporting month-end close, performing reconciliations and integrity checks, and preparing monthly management reporting in a multinational environment across time zones.
  • At least 3 years of experience with forecasting, budgeting, and performance management, including leading forecasting processes, coordinating cross-functional inputs, validating assumptions, and preparing narrative drivers and variance explanations for senior leadership review.
  • At least 3 years of experience implementing data analysis and automation tools, including advanced Excel with VBA or macros and emerging artificial intelligence-enabled tools.
  • At least 3 years of experience with finance business partnering and executive communication, including building executive reports and presentation decks and translating complex financial performance into actionable insights.
  • At least 3 years of experience with financial modeling and profitability analytics, including driver-based profitability and performance modeling and revenue and profit-and-loss variance drivers.
  • At least 3 years of experience with headcount and resource planning analytics, including full-time-equivalent reporting and headcount trend analysis to support resource allocation decisions.
  • At least 3 years of experience with financial reporting governance and internal controls, including establishing reporting processes, defining standard metrics, documenting standard operating procedures, and ensuring data integrity and compliance with internal standards.
  • At least 3 years of experience with enterprise finance systems and data structures, including enterprise resource planning, consolidation, and planning or reporting environments such as SAP or comparable enterprise finance platforms, and interpreting system outputs for management reporting.
Responsibilities
  • Utilize, synthesize, and integrate confidential financial and operational datasets, including profit-and-loss, balance sheet, cash flow, headcount and full-time-equivalent, sales, and expense drivers, to generate insights that guide results and strategy and help senior decision makers identify value-adding opportunities.
  • Apply internal protocols and standard operating procedures to execute annual business planning, monthly forecasting, periodic performance reporting, and month-end close activities.
  • Establish and maintain financial reporting systems, processes, and internal controls, including data validation, reconciliations, variance analysis, and integrity checks, to ensure reliability and compliance with Roche standards for financial statements and management information.
  • Develop and maintain analytics, insights, and financial modeling tools to support analysis of sales drivers, price and volume, cost of goods sold, and headcount trends.
  • Prepare executive reports and presentation decks for monthly United States Leadership Team meetings.
  • Lead local forecasting and Monthly Outlook cycles by coordinating organizational inputs, validating assumptions, preparing narratives and reporting on drivers and variances, and delivering consolidated forecasts and models for the United States Leadership Team.
  • Integrate technology and automation into insight-generation processes by automating recurring reporting and commentary collection, developing standard templates, training stakeholders, scaling expertise for future efforts, and streamlining processes across the organization.
  • Partner with global finance stakeholders, including Strategic Finance, the Enterprise Center of Excellence, and regional and global finance teams, and with senior leaders to align on processes and validate assumptions and performance drivers.
  • Support strategic and operational decision-making across time zones.
  • Provide finance business partnering support to enabling functions by advising on budgets, forecasts, resource planning, and performance tracking.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.